Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.81B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 1.02M
Average 0.71M
ZYME Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Zymeworks Inc.NASDAQ: ZYME
Accounts Payables · Q3 FY2026 · quarter ended Sep 2026
Accounts payables growth accelerates
Q3 FY2026 accounts payables of $55.07M rose 1548.2% year over year, ahead of the +357.1% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 22.3% of revenue in FY2025, up 3.5 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1548.2% holds above the trailing-twelve-month pace of +357.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (23.65M) USD
- Year-over-year change
- -265.0%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23.65M) | -265.0% |
| FY2024 | 2024-12-31 | 14.34M | +132.0% |
| FY2023 | 2023-12-31 | (44.77M) | -269.1% |
| FY2022 | 2022-12-31 | 26.48M | +60.7% |
| FY2021 | 2021-12-31 | 16.48M | — |
Accounts Payables vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 accounts payables of $45.36M is the largest of the 11 companies compared; the peer median is $119.68K.
- Its year-over-year change of +357.1% is the 2nd highest of 10, against a peer median of -91.2%.
- Accounts payables amounts to 17.1% of revenue for ZYME, versus a peer median of 3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $45.36M | +357.1% | — | 17.1% | |
| LTM Aug 2026 | $25.05M | +537.3% | — | 3.6% | |
| LTM Sep 2026 | $13.63M | -5.5% | +52.3% | 12167.9% | |
| LTM Mar 2026 | $10.3M | -925.0% | — | 13.0% | |
| LTM Jun 2026 | $6.13M | -229.5% | +0.3% | 5.8% | |
| LTM Mar 2026 | $2.31M | -48.2% | -70.5% | 1.5% | |
| LTM Sep 2026 | $1.13M | -147.6% | +138.3% | — | |
| LTM Mar 2026 | $1.09M | +164.9% | +48.1% | 3.1% | |
| LTM Mar 2026 | $233K | -91.2% | -54.6% | — | |
| LTM Mar 2026 | $6.37K | -100.5% | — | 0.1% | |
| LTM Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding ZYME) | $119.68K | -91.2% | +24.2% | 3.3% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| Deferred Income Tax | (953K) | 1.94M | (757K) | 691K | 945K |
| Stock-Based Compensation | 10.76M | 4.02M | 8.1M | 17.79M | 28.03M |
| Change in Working Capital | 393K | 4.02M | (25.55M) | (30.95M) | 7.5M |
| Accounts Receivables | (266K) | (17.51M) | 13.92M | (36.36M) | 51.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.48M | 26.48M | (44.77M) | 14.34M | (23.65M) |
| Other Working Capital | (15.82M) | (4.96M) | 5.3M | (8.93M) | (20.05M) |
| Other Non-Cash Items | (387K) | (2.21M) | 1.27M | 13.93M | 532K |
| Operating Cash Flow | (192.45M) | 144.11M | (118.3M) | (110.04M) | (33.01M) |
| Capital Expenditures | (13.29M) | (13.13M) | (4.08M) | (3.07M) | (1.52M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.08M) | (40.72M) | (553.25M) | (283.74M) | (196.06M) |
| Sales of Investments | 192.96M | (40.72M) | 350.07M | 325.57M | 225.08M |
| Other Investing Activities | (881K) | 40.72M | (1.6M) | (1.08M) | 0 |
| Investing Cash Flow | 144.6M | (53.85M) | (207.25M) | 38.76M | 26.66M |
| Debt Repayment | (17K) | (14K) | (21K) | (14K) | 0 |
| Common Stock Issued | 0 | 107.53M | 76.1M | 0 | 23.32M |
| Common Stock Repurchased | 0 | 0 | 0 | (30.05M) | (41.7M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.03M | 1.06M | 5.77M | 9.61M | (181K) |
| Financing Cash Flow | 8.01M | 108.58M | 81.85M | (20.45M) | (18.56M) |
| Effect of Forex Changes | (325K) | 203K | 354K | 286K | (45K) |
| Net Change in Cash | (40.17M) | 199.05M | (243.36M) | (91.45M) | (24.95M) |
| Free Cash Flow | (205.74M) | 130.98M | (122.38M) | (113.11M) | (34.53M) |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$26.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.